Cure CMD

“The 990 is prepared by the Treasurer of the organization based on financial statements recorded in the organizations accounting system. Financial reports are presented quarterly to the board and reviewed during quarterly meetings. The completed 990 is presented to the executive director upon completion.”

“The organization reviews the conflict of interest policy every two years and periodically asks its board members to attest to their adherence to the policy.”

“The organizations governing documents conflict of interest policy and financial statements are available to the public upon written request.”

“| Explanation:| Research Strategy - Scientific research provides the foundation for understanding the causes and course of disease and provides the opportunity to develop the tools necessary for establishing treatments that will slow stop or even reverse CMD symptom progression. Everyone living with a congenital muscular dystrophy has unmet needs and addressing those needs is at the core of Cure CMDs mission. We identify scientists and clinicians from around the world with a wide variety of expertise to remove treatment roadblocks building a rich and adaptable research environment that capitalizes on new technologies as they arise. We shepherd CMD research growth and breakthroughs and monitor advances in other neuromuscular conditions that could impact our own progress continually refining priorities that are responsive to the needs of our affected community. We participate in and often host scientific meetings that share and interrogate research progress while communicating the needs of our affected community to researchers so that their priorities are aligned. We encourage the interest and eagerness of young scientists encouraging them to continue careers focused on CMD research after completing their fellowships. Our Scientific Director stays abreast of the latest research publications to better understand and incorporate scientific progress and breakthroughs into our research plan and identify synergies between labs working in similar areas. Perhaps most importantly we maintain a continuous dialogue with the CMD community and expert clinicians to understand the evolving needs and priorities of affected individuals ensuring that we continue to fund the most promising research and clinical developments through our patient-centered vision.”